Clinics in Dermatology
Volume 28, Issue 1 , Pages 45-51 , January 2010

The historical basis of a misconception leading to undertreating atopic dermatitis (eczema):facts and controversies

  • David Farhi, MD

      Affiliations

    • Service de Dermatologie, Pavillon Tarnier, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Faculté de Médecine, Université René Descartes - Paris V, 27 rue du faubourg Saint Jacques, 75014 Paris, France
    • Corresponding Author InformationCorresponding author. Department of Dermatology and Venereology, Pavillon Tarnier, CHU Cochin, 89 rue d'Assas, 75006 Paris, France; Tel.: +33 1 58 41 18 34; fax: +33 1 58 41 17 65.
    • ,
  • Alain Taïeb, MD

      Affiliations

    • Service de Dermatologie et Dermatologie Pédiatrique, Centre de Référence pour les Maladies Rares de la Peau, CHU Saint André, 1 rue Jean Burguet, 33000 Bordeaux, France
    • ,
  • Gérard Tilles, MD

      Affiliations

    • Musée de l'hôpital Saint Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France
    • ,
  • Daniel Wallach, MD

      Affiliations

    • Service de Dermatologie, Pavillon Tarnier, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Faculté de Médecine, Université René Descartes - Paris V, 27 rue du faubourg Saint Jacques, 75014 Paris, France

References 

  1. Tilles G, Wallach D, Taieb A. Topical therapy of atopic dermatitis: controversies from Hippocrates to topical immunomodulators. J Am Acad Dermatol. 2007;56:295–301
  2. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151–160
  3. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med. 2005;352:2314–2324
  4. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931–936
  5. Alibert JL. In: Précis théorique et pratique des maladies de la peau. Paris: Crapart, Caille et Ravier; 1818;p. 347
  6. Cazenave PLA. In: Abrégé pratique des maladies de la peau, 4ème ed. Paris: Béchet jeune; 1848;p. 47
  7. Gaucher E. Pathogénie et métastases de l'eczéma particulièrement chez les enfants. In:  Feulard H editors. Congrès International de Dermatologie et de Syphiligraphie (Paris, 1889). Paris: Masson; 1890;p. 542–545
  8. Gaucher E. In: Leçons sur les maladies de la peau. Paris: Doin; 1895;p. 224–225
  9. Gougerot H. In: La dermatologie en clientèle. Paris: Maloine; 1939;p. 132
  10. Besnier E. Emploi des tissus imperméables et notamment de la toile de caoutchouc dans les traitement des affections de la peau. Bull Thérap. 1875;88:49–64
  11. Colson A. De l'emploi de la toile de caoutchouc vulcanisée dans les maladies dartreuses. Gaz Hop Paris. 1869;2:89–90
  12. Hebra F. In: Traité des maladies de la peau, traduit et annoté par le docteur A Doyon. Paris: Masson; 1872;p. 560
  13. Kaposi M. In: Pathologie et traitement des maladies de la peau, traduit par E Besnier et A Doyon, 2ème ed. Paris: Masson; 1891;p. 105–107
  14. Marfan AB. In: Les eczémas du nourrisson, leur rapports avec les vices de l'alimentation et les troubles digestifs. Paris: Steinheil; 1894;p. 13–14
  15. Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr. 1985;107:669–675
  16. Sampson HA. Food allergy. Part 1: immunopathogenesis and clinical disorders. J Allergy Clin Immunol. 1999;103:717–728
  17. Coca AF, Cooke RA. On the classification of the phenomena of hypersensitiveness. J Immunol. 1923;8:163–182
  18. Wise F, Sulzberger MB. In: Year book of dermatology and syphilology. Chicago: Year Book Medical Publishers; 1933;p. 31–70
  19. Hill LW, Sulzberger MB. Evolution of atopic dermatitis. Arch Dermatol Syphilol. 1935;32:451–463
  20. Guillet G, Guillet MH. Natural history of sensitizations in atopic dermatitis. A 3-year follow-up in 250 children: food allergy and high risk of respiratory symptoms. Arch Dermatol. 1992;128:187–192
  21. Sinagra JL, Bordignon V, Ferraro C, et al. Unnecessary milk elimination diets in children with atopic dermatitis. Pediatr Dermatol. 2007;24:1–6
  22. Pham Thi N, De Blic J. Food allergy, environment and primary and secondary prevention of atopic dermatitis. Ann Dermatol Venereol. 2005;132(Spec No 1):S228–S242
  23. Juhlin L, Johansson GO, Bennich H, Hogman C, Thyresson N, Immunoglobulin E. in dermatoses. Levels in atopic dermatitis and urticaria. Arch Dermatol. 1969;100:12–16
  24. Bruynzeel-Koomen C, van Wichen DF, Toonstra J, Berrens L, Bruynzeel PL. The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis. Arch Dermatol Res. 1986;278:199–205
  25. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–1494
  26. Maintz L, Novak N. Getting more and more complex: the pathophysiology of atopic eczema. Eur J Dermatol. 2007;17:267–283
  27. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259–1260
  28. Flohr C, Pascoe D, Williams HC. Atopic dermatitis and the ‘hygiene hypothesis’: too clean to be true?. Br J Dermatol. 2005;152:202–216
  29. Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol. 2003;49:1088–1095
  30. Caramia G, Atzei A, Fanos V. Probiotics and the skin. Clin Dermatol. 2008;26:4–11
  31. Metchnikoff E. In: The prolongation of life. New York: Puman and Sons; 1907;p. 1–38
  32. Sepp E, Julge K, Vasar M, Naaber P, Bjorksten B, Mikelsaar M. Intestinal microflora of Estonian and Swedish infants. Acta Paediatr. 1997;86:956–961
  33. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003;361:1869–1871
  34. Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol. 1952;19:101–102
  35. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005;330:516
  36. Lapsley P. Itching for a solution. BMJ. 2005;330:522
  37. Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol. 2003;28:549–553
  38. Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic DermatitisStudy Group. Br J Dermatol. 1999;140:1114–1121
  39. Thomas KS, Armstrong S, Avery A, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ. 2002;324:768
  40. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ. 2003;326:1367
  41. Bewley A. Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids. Br J Dermatol. 2008;158:917–920
  42. Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol. 2005;53:S186–S194
  43. Koo JY, Fleischer AB, Abramovits W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol. 2005;53:S195–S205
  44. Beck LA. The efficacy and safety of tacrolimus ointment: a clinical review. J Am Acad Dermatol. 2005;53:S165–S170
  45. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007;156:203–221
  46. Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006;54:818–823
  47. Ogawa H, Yoshiike T. A speculative view of atopic dermatitis: barrier dysfunction in pathogenesis. J Dermatol Sci. 1993;5:197–204
  48. Taieb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact Dermatitis. 1999;41:177–180
  49. Brenninkmeijer EE, Schram ME, Leeflang MM, Bos JD, Spuls PI. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158:754–765
  50. Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131:383–396
  51. Diepgen TL, Fartasch M. Recent epidemiological and genetic studies in atopic dermatitis. Acta Derm Venereol. 1992;176:13–18
  52. Williams HC, Burney PG, Pembroke AC, Hay RJ. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. U.K. Diagnostic Criteria for Atopic Dermatitis Working Party. Br J Dermatol. 1996;135:12–17
  53. Abramovits W. Atopic dermatitis. J Am Acad Dermatol. 2005;53:S86–S93
  54. Loden M. Biophysical properties of dry atopic and normal skin with special reference to effects of skin care products. Acta Derm Venereol Suppl (Stockh). 1995;192:1–48
  55. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med. 1999;341:1817–1828
  56. Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin?. J Invest Dermatol. 1991;96:523–526
  57. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441–446
  58. Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 2006;118:214–219
  59. Girolomoni G, Pastore S. The role of keratinocytes in the pathogenesis of atopic dermatitis. J Am Acad Dermatol. 2001;45:S25–S28
  60. Breuhahn K, Mann A, Muller G, et al. Epidermal overexpression of granulocyte-macrophage colony-stimulating factor induces both keratinocyte proliferation and apoptosis. Cell Growth Differ. 2000;11:111–121
  61. Biedermann T, Rocken M, Carballido JM. TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin. J Investig Dermatol Symp Proc. 2004;9:5–14
  62. Hoffjan S, Epplen JT. The genetics of atopic dermatitis: recent findings and future options. J Mol Med. 2005;83:682–692
  63. Cookson WO, Ubhi B, Lawrence R, et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet. 2001;27:372–373
  64. Sugiura H, Ebise H, Tazawa T, et al. Large-scale DNA microarray analysis of atopic skin lesions shows overexpression of an epidermal differentiation gene cluster in the alternative pathway and lack of protective gene expression in the cornified envelope. Br J Dermatol. 2005;152:146–149
  65. Seguchi T, Cui CY, Kusuda S, Takahashi M, Aisu K, Tezuka T. Decreased expression of filaggrin in atopic skin. Arch Dermatol Res. 1996;288:442–446
  66. Nomura T, Sandilands A, Akiyama M, et al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007;119:434–440
  67. Weidinger S, Rodriguez E, Stahl C, et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol. 2007;127:724–726
  68. Morar N, Cookson WO, Harper JI, Moffatt MF. Filaggrin mutations in children with severe atopic dermatitis. J Invest Dermatol. 2007;127:1667–1672
  69. Hoffjan S, Stemmler S. On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. Br J Dermatol. 2007;157:441–449
  70. Yamamoto K. The environment in atopic dermatitis. In:  Gelmetti C editors. Pediatric dermatology: controversies and current concepts. New York: DM Medical Publishing; 1994;
  71. Leung DY, Harbeck R, Bina P, et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest. 1993;92:1374–1380
  72. Breuer K, Wittmann M, Bosche B, Kapp A, Werfel T. Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). Allergy. 2000;55:551–555
  73. Strange P, Skov L, Lisby S, Nielsen PL, Baadsgaard O. Staphylococcal enterotoxin B applied on intact normal and intact atopic skin induces dermatitis. Arch Dermatol. 1996;132:27–33
  74. Lester MR, Hofer MF, Renz H, Trumble AE, Gelfand EW, Leung DY. Modulatory effects of staphylococcal superantigen TSST-1 on IgE synthesis in atopic dermatitis. Clin Immunol Immunopathol. 1995;77:332–338
  75. Esche C, de Benedetto A, Beck LA. Keratinocytes in atopic dermatitis: inflammatory signals. Curr Allergy Asthma Rep. 2004;4:276–284
  76. Leyden JJ, Kligman AM. The case for steroid–antibiotic combinations. Br J Dermatol. 1977;96:179–187
  77. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol. 1992;27:29–34
  78. Remitz A, Kyllonen H, Granlund H, Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol. 2001;107:196–197
  79. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347:1151–1160
  80. Abramovits W. A clinician's paradigm in the treatment of atopic dermatitis. J Am Acad Dermatol. 2005;53:S70–S77

PII: S0738-081X(09)00055-8

doi: 10.1016/j.clindermatol.2009.03.009

Clinics in Dermatology
Volume 28, Issue 1 , Pages 45-51 , January 2010

Article Tools